Nykode Therapeutics Stock
Stocks
VACC
NO0010714785
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Oslo Bors
22:45:00 18/09/2026 HKT
|
5-day change | 1st Jan Change | ||
| 4.050 NOK | +0.75% |
|
+0.25% | +67.91% |
| 08-28 | Nykode Therapeutics Raises NOK286 Million via Share Placement | MT |
| 08-27 | ABG Sundal Collier raises the target price for Nykode Therapeutics to 7.0 Norwegian kroner (4.5), reiterates buy | FW |
| Market Cap | 1.32B 140M 122M 116M 105M 197M 13.46B 197M 1.38B 534M 6.84B 527M 515M 22.02B | P/E 2026 * |
-6.22x | P/E 2027 * | 83.5x |
|---|---|---|---|---|---|
| Enterprise Value | 838M 88.94M 77.56M 73.23M 66.5M 125M 8.53B 125M 877M 339M 4.34B 334M 327M 13.96B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | 3.31x |
| Free-Float |
76.21% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Oslo Bors
| VACC | Real-time | |
CBOE
| Real-time | ||
|
Nasdaq Stockholm
| NYKD O | Delayed | |
|
OTC Markets
| VACBF | Delayed | |
|
Börse Stuttgart
| 5VB | Delayed | |
|
Boerse Muenchen
| 5VB | Real-time | |
|
Deutsche Boerse AG
| 5VB | Delayed | |
|
CBOE
| Real-time |
Last Transcript: Nykode Therapeutics
| 1 day | +0.75% | ||
| 1 week | +0.25% | ||
| Current month | -5.59% | ||
| 1 month | +20.90% | ||
| 3 months | +29.19% | ||
| 6 months | +37.10% | ||
| Current year | +67.91% |
| 1 week | 3.76 |  | 4.2 |
| 1 month | 3.2 | | 5.2 |
| Current year | 2.21 | | 5.2 |
| 1 year | 1.5 | | 5.2 |
| 3 years | 1.44 | | 29.52 |
| 5 years | 1.44 | | 85.3 |
| 10 years | 1.44 | | 93 |
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Engsig
CEO | Chief Executive Officer | 54 | 01/01/2019 |
| President | 49 | 01/01/2017 | |
Harald Gurvin
DFI | Director of Finance/CFO | 51 | 03/05/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 54 | - | |
Trygve Lauvdal
BRD | Director/Board Member | 57 | - |
Susanne Stuffers
CHM | Chairman | 45 | 23/04/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 27/3/25 | Buy | Company | 3,000,000 | 0.9187% | ||
| 20/12/24 | Buy | Director | 100,000 | 0.0306% | ||
| 20/12/24 | Sell | Director | 100,000 | 0.0306% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.75% | +0.25% | +170.00% | -85.07% | 139M | |
| -0.31% | +3.56% | +46.40% | +100.50% | 70.89B | |
| +0.39% | +1.82% | +38.93% | +77.73% | 62.32B | |
| -3.21% | -7.27% | -17.73% | +351.98% | 27.07B | |
| -2.64% | -0.69% | -0.26% | -11.90% | 24.78B | |
| +0.71% | +8.50% | +27.76% | -15.29% | 20.59B | |
| -1.26% | -10.61% | +170.72% | +290.48% | 15.52B | |
| -0.22% | +3.99% | +44.28% | +173.35% | 14.49B | |
| +0.73% | +1.71% | -7.18% | +886.19% | 14.14B | |
| -0.54% | -0.56% | +20.59% | +224.93% | 12.35B | |
| Average | -0.56% | +1.46% | +49.35% | +199.29% | 26.23B | |
| Weighted average by Cap. | -0.59% | +1.39% | +35.34% | +164.70% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | 210M 22.27M 19.42M 18.34M 16.65M 31.2M 2.14B 31.33M 220M 84.77M 1.09B 83.67M 81.81M 3.5B |
| Net income | -209M -22.22M -19.38M -18.3M -16.62M -31.13M -2.13B -31.26M -219M -84.58M -1.08B -83.48M -81.63M -3.49B | 9.97M 1.06M 922K 871K 790K 1.48M 101M 1.49M 10.43M 4.02M 51.58M 3.97M 3.88M 166M |
| Net Debt | -484M -51.37M -44.79M -42.29M -38.4M -71.95M -4.93B -72.26M -507M -195M -2.51B -193M -189M -8.06B | -628M -66.67M -58.14M -54.89M -49.85M -93.4M -6.4B -93.79M -658M -254M -3.25B -250M -245M -10.47B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 18/09/26 | NOK 4.050 | +0.75% | 2,143,022 |
| 17/09/26 | NOK 4.020 | +2.42% | 761,275 |
| 16/09/26 | NOK 3.925 | +3.02% | 977,792 |
| 15/09/26 | NOK 3.810 | -1.30% | 1,221,177 |
| 14/09/26 | NOK 3.860 | -2.28% | 1,288,557 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- VACC Stock
Select your edition
All financial news and data tailored to specific country editions
